| 1 |
中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-直肠癌(2024 版) [J]. 中华结直肠疾病电子杂志, 2025, 14(1): 1-19.
|
| 2 |
André T, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase Ⅲ KEYNOTE-177 study [J]. Ann Oncol, 2025, 36(3): 277-284.
|
| 3 |
André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer [J]. N Engl J Med, 2020, 383(23): 2207-2218.
|
| 4 |
Williams CJM, Peddle AM, Kasi PM, et al. Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response [J]. Nat Rev Clin Oncol, 2024, 21(12): 839-851.
|
| 5 |
Zhang Y, Wang D, Zhang K, et al. First-line treatment with a combination of immunotherapy, anti-EGFR monoclonal antibodies, and chemotherapeutics for unresectable left KRAS/BRAF wild-type microsatellite-stable colorectal cancer: a case report [J]. Anticancer Drugs, 2025, 36(8): 686-690.
|
| 6 |
Bullock AJ, Schlechter BL, Fakih MG, et al. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial [J]. Nat Med, 2024, 30(9): 2558-2567.
|
| 7 |
Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies [J]. Nat Rev Drug Discov, 2019, 18(3): 197-218.
|
| 8 |
Lin KX, Istl AC, Quan D, et al. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies [J]. Cancer Immunol Immunother, 2023, 72(12): 3875-3893.
|
| 9 |
Al Zein M, Boukhdoud M, Shammaa H, et al. Immunotherapy and immunoevasion of colorectal cancer [J]. Drug Discov Today, 2023, 28(9): 103669.
|
| 10 |
Yu H, Liu S, Yuan Z, et al. Targeted co-delivery of rapamycin and oxaliplatin by liposomes suppresses tumor growth and metastasis of colorectal cancer [J]. Biomed Pharmacother, 2024, 178: 117192.
|
| 11 |
Pozzi C, Cuomo A, Spadoni I, et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death [J]. Nat Med, 2016, 22(6): 624-631.
|
| 12 |
Feng Y, Ma W, Zang Y, et al. Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients [J]. Nat Commun, 2024, 15(1): 10259.
|
| 13 |
Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer [J]. Signal Transduct Target Ther, 2020, 5(1): 22.
|
| 14 |
Pavelescu LA, Enache RM, Roşu OA, et al. Predictive biomarkers and resistance mechanisms of checkpoint inhibitors in malignant solid tumors [J]. Int J Mol Sci, 2024, 25(17): 9659.
|
| 15 |
Yang X, Yan Y, Wang F, et al. Aspirin prevents colorectal cancer by regulating the abundance of Enterococcus cecorum and TIGIT(+)Treg cells [J]. Sci Rep, 2024, 14(1): 13592.
|
| 16 |
曹飞, 庞俊. 前列腺癌免疫微环境中免疫抑制性细胞分类及其作用机制[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(2): 121-125.
|
| 17 |
Gomez-Roca C, Cassier P, Zamarin D, et al. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade [J]. J Immunother Cancer, 2022, 10(5): e004076.
|
| 18 |
Sung E, Ko M, Won JY, et al. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation [J]. Mol Ther, 2022, 30(8): 2800-2816.
|
| 19 |
Zhang Y, Chen H, Mo H, et al. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer [J]. Cancer Cell, 2025, 43(3): 446-463.e7.
|
| 20 |
Su C, Liao Z, Mo J, et al. VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization [J]. Nat Commun, 2025, 16(1): 9027.
|
| 21 |
Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies [J]. Cancer Immunol Res, 2015, 3(5): 436-443.
|
| 22 |
Xue J, Yu X, Xue L, et al. Intrinsic β-catenin signaling suppresses CD8(+) T-cell infiltration in colorectal cancer [J]. Biomed Pharmacother, 2019, 115: 108921.
|
| 23 |
Toulmonde M, Guégan JP, Spalato-Ceruso M, et al. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab [J]. Signal Transduct Target Ther, 2025, 10(1): 202.
|
| 24 |
苏燕燕, 杨翀, 张宗祥, 等. 瑞戈非尼通过CSF1-R信号通路调节肿瘤相关巨噬细胞增强PD-1抗体在结直肠癌中疗效的研究 [J]. 浙江中西医结合杂志, 2023, 33(10): 909-914.
|
| 25 |
Jiang M, Chen P, Wang L, et al. cGAS-STING, an important pathway in cancer immunotherapy [J]. J Hematol Oncol, 2020, 13(1): 81.
|
| 26 |
Zhigarev D, Varshavsky A, MacFarlane AW 4th, et al. Lymphocyte exhaustion in AML patients and impacts of HMA/venetoclax or intensive chemotherapy on their biology [J]. Cancers (Basel), 2022, 14(14): 3352.
|
| 27 |
Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors [J]. Nat Rev Clin Oncol, 2020, 17(12): 725-741.
|
| 28 |
Lenz HJ, Parikh A, Spigel DR, et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial [J]. J Immunother Cancer, 2024, 12(3): e008409.
|
| 29 |
Antoniotti C, Rossini D, Pietrantonio F, et al. Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study [J]. J Clin Oncol, 2024, 42(22): 2637-2644.
|
| 30 |
Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603) [J]. J Clin Oncol, 2020, 38(18): 2053-2061.
|
| 31 |
Fakih M, Sandhu J, Lim D, et al. Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: A phase 1 nonrandomized clinical trial [J]. JAMA Oncol, 2023, 9(5): 627-634.
|
| 32 |
Nie C, Lv H, Chen B, et al. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study [J]. Front Oncol, 2022, 12: 917353.
|
| 33 |
Tian J, Chen JH, Chao SX, et al. Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial [J]. Nat Med, 2023, 29(2): 458-466.
|
| 34 |
Wang F, Zhao Q, Wang YN, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types [J]. JAMA Oncol, 2019, 5(10): 1504-1506.
|
| 35 |
El Hajj J, Reddy S, Verma N, et al. Immune checkpoint inhibitors in pMMR/MSS colorectal cancer [J]. J Gastrointest Cancer, 2023, 54(4): 1017-1030.
|
| 36 |
Kim R, Tehfe M, Kavan P, et al. Pembrolizumab plus mFOLFOX7 or FOLFIRI for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer: KEYNOTE-651 cohorts B and D [J]. Clin Colorectal Cancer, 2024, 23(2): 118-127.e6.
|
| 37 |
Fang X, Zhong C, Weng S, et al. Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study [J]. BMC Cancer, 2023, 23(1): 676.
|
| 38 |
Wang L, Zhang T, Pan Q, et al. A phase Ⅱ study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and hepatic artery infusion chemotherapy (HAIC) for advanced colorectal cancer liver metastases: An updated analysis of survival [J]. J Clin Oncol, 2024, 42(16_suppl): 3543-3543.
|
| 39 |
Wang Z, Ouyang H, Luo H, et al. A phase Ⅱ clinical evaluation of radiofrequency ablation (RFA) combined with regorafenib and toripalimab in patients with colorectal cancer with liver metastases [J]. J Clin Oncol, 2024, 42(16_suppl): 3566-3566.
|
| 40 |
Wu C, Shao Y, Gu W. Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer [J]. Clin Transl Oncol, 2023, 25(7): 1916-1928.
|
| 41 |
Zhou P, Wang Y, Qin S, et al. Abscopal effect triggered by radiation sequential mono-immunotherapy resulted in a complete remission of PMMR sigmoid colon cancer [J]. Front Immunol, 2023, 14: 1139527.
|
| 42 |
Zhang Y, Guan H, Liu S, et al. Gamma knife stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: a phase II trial analysis [J]. Elife, 2025, 14: RP103559.
|
| 43 |
Ni J, Wan CG, Sui ZQ. Efficacy and safety of radiotherapy in patients with microsatellite stable or proficient mismatch repair colorectal cancer liver metastasis [J]. World J Gastrointest Oncol, 2025, 17(3): 102873.
|
| 44 |
He F, Yao Q, Pei F, et al. Stereotactic body radiotherapy combined with PD-1 antibody in unresectable colorectal liver metastases: A prospective, multicenter, single-arm, phase Ⅱ study (SPARKLE-L) [J]. J Clin Oncol, 2025, 43(16_suppl): TPS3639-TPS.
|
| 45 |
Li X, Shan Z, Shen L, et al. 146TiP MIRACLE3: Phase Ⅱ study of ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases [J]. Annals of Oncology, 2025, 36: S61.
|
| 46 |
Wang F, Jin Y, Wang M, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial [J]. Nat Med, 2024, 30(4): 1035-1043.
|
| 47 |
Morano F, Raimondi A, Pagani F, et al. Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O(6)-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: The MAYA trial [J]. J Clin Oncol, 2022, 40(14): 1562-1573.
|
| 48 |
Dai T, Sun H, Liban T, et al. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody [J]. Sci Rep, 2024, 14(1): 10661.
|
| 49 |
Guo L, Hu C, Liu Y, et al. Directed natural evolution generates a next-generation oncolytic virus with a high potency and safety profile [J]. Nat Commun, 2023, 14(1): 3410.
|
| 50 |
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [J]. Lancet Oncol, 2017, 18(3): e143-e52.
|
| 51 |
中华医学会外科学分会结直肠外科学组, 中国研究型医院学会结直肠肛门外科专委会, 中国结直肠临床研究协作组. 错配修复功能完整和(或)微卫星稳定型局部进展期直肠癌患者短程放疗序贯化疗联合免疫治疗的新辅助治疗专家共识(2025版) [J]. 实用肿瘤杂志, 2025, 40(5): 391-399.
|
| 52 |
Sun HC, Zhou J, Wang Z, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition) [J]. Hepatobiliary Surg Nutr, 2022, 11(2): 227-252.
|
| 53 |
Zhao G, Zhang H, Xu F, et al. Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage Ⅲ non-small-cell lung cancer: a retrospective cohort study [J]. Transl Lung Cancer Res, 2023, 12(1): 141-149.
|
| 54 |
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J]. Lancet, 2013, 381(9863): 303-312.
|
| 55 |
Rached L, Laparra A, Sakkal M, et al. Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations [J]. Cancer Treat Rev, 2024, 127: 102751.
|
| 56 |
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade [J]. N Engl J Med, 2018, 378(2): 158-168.
|
| 57 |
Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years [J]. J Clin Oncol, 2012, 30(16): 1926-1933.
|
| 58 |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet, 2014, 384(9938): 164-172.
|
| 59 |
Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial [J]. J Clin Oncol, 2014, 32(15): 1554-1562.
|
| 60 |
Chen B, Zhao H, Huang J, et al. Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer [J]. BMC Geriatr, 2022, 22(1): 987.
|